Does BPC 157 Cause Cancer?

Your body already runs a blood vessel construction system, and BPC-157 turns up the volume on it.

That system works through something called VEGF, which stands for vascular endothelial growth factor, and it functions essentially as a chemical signal your tissues send out when they need more blood supply. When you tear a tendon or damage muscle, the injured cells release VEGF, nearby blood vessels detect that signal through receptors on their surface, and the process of building new vessels toward the damage begins. BPC-157 amplifies this process by increasing the number of those receptors, specifically something called VEGFR2, which is the primary receptor that cells use to detect the VEGF signal and trigger vessel growth.

A 2017 study using a rat hind limb ischemia model, where blood flow to the limb is deliberately cut off, found that BPC-157 activated the VEGFR2-Akt-eNOS signaling pathway and produced measurably higher vessel density in ischemic tissue compared to controls. That is the healing mechanism. More receptors means the tissue becomes more sensitive to the circulating VEGF signal, vessels grow toward the damage faster, and healing speeds up.

Now here is where the cancer question comes in.

Tumors use that exact same VEGF pathway. When a solid tumor grows beyond roughly one to two millimeters in diameter, it can no longer survive on passive oxygen diffusion from surrounding tissue, so it starts secreting VEGF itself to recruit new blood vessels into the tumor mass. This process is called angiogenesis, which is the formation of new blood vessels from existing ones, and it is what allows a small tumor to become a large one. Without it, tumors hit a growth ceiling and stall. With it, they get the fuel they need to expand and eventually metastasize.

This is not a theoretical connection. Some of the most established cancer drugs on the market work specifically by blocking VEGF signaling. Bevacizumab, for example, is an antibody that binds circulating VEGF and prevents it from reaching receptors, which starves tumors of the blood supply they are trying to build. The fact that blocking this pathway is a viable cancer treatment is what makes the BPC-157 question worth asking seriously.

If BPC-157 upregulates VEGFR2 and makes cells more sensitive to VEGF signals, could it accelerate blood vessel recruitment into a tumor that someone does not know they have?

The honest answer is that nobody has tested this in a living organism with an actual tumor, and that gap in the data is the whole problem.

The only study that directly tested BPC-157 against cancer cells was a 2004 conference abstract by researchers in the Sikiric lab, the same group that has done most of the foundational BPC-157 research. They applied BPC-157 to the SK-Mel-1 human melanoma cell line in culture at concentrations of 2 nanograms and 10 nanograms and measured what happened to cell division. The finding was that BPC-157 reduced the total S-phase fraction, which is the portion of cells actively copying their DNA in preparation for division, by up to 55% compared to controls.

That sounds like a protective effect, and it might be. But it is one study, in one cell line, in a dish, by one affiliated research group, never independently replicated in over 20 years. A 2025 published commentary in Pharmaceuticals noted explicitly that no published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis in any animal model. The jump from a cultured melanoma cell line responding to BPC-157 in a petri dish to concluding that BPC-157 is safe around tumors in a living body with a functional immune system, active tumor microenvironment, and circulating growth factors is not a jump the current data supports.

The same 2025 commentary raised an additional concern that the video did not have time to address. BPC-157 also activates something called the FAK-paxillin signaling pathway, where FAK stands for focal adhesion kinase, and this pathway plays a documented role in cancer cell invasion and migration. FAK-paxillin signaling helps cells detach from their anchors and move through surrounding tissue, which is one of the mechanisms involved in metastasis. Whether BPC-157's activation of this pathway is meaningful in the context of a real tumor is unknown, but it adds a second theoretical mechanism that points in a concerning direction, not just the VEGF story.

So the picture looks like this. BPC-157 has one plausible mechanism that could help tumors grow by amplifying blood vessel recruitment, and a second plausible mechanism that could help cancer cells move and invade, and one unreplicated in vitro study suggesting it might actually inhibit cell division in one cancer type, and zero animal or human studies that test any of these effects in a living body with an actual tumor. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine concluded that BPC-157 should be considered investigational until well-designed human trials are conducted.

That is the actual state of the evidence.

For someone with no cancer history and no known high-risk conditions, the theoretical risk from an occasional course of BPC-157 is probably low, but that word theoretical is doing a lot of work there because the data to confirm or deny it simply does not exist. For someone with active cancer, a history of cancer, or a known precancerous condition like high-grade dysplasia or certain polyp subtypes, using a compound that upregulates VEGFR2 and activates FAK-paxillin signaling before anyone has tested its effects on tumor biology in a living system is a risk that cannot currently be quantified.

The reason this matters beyond BPC-157 specifically is that most people evaluating peptides are doing it the wrong way around. They are asking whether there is evidence of harm, and when they find none, treating that as clearance. But the absence of evidence that something causes cancer is not the same as evidence that it does not, and the VEGF and FAK-paxillin connections are not paranoid speculation, they are established biology. The question is simply whether that biology plays out the way it theoretically could in a real human body, and that question has not been answered.

The screenings matter for exactly that reason. A subclinical tumor you do not know about cannot inform your decision about whether to use a compound that upregulates the signaling pathway that tumor needs to grow.

---

References

1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. Study conditions: Rat hind limb ischemia model and human umbilical vein endothelial cell cultures. Did not test tumor models. Finding: BPC-157 increased VEGFR2 expression and activated the VEGFR2-Akt-eNOS signaling pathway, increasing vessel density in ischemic tissue.
2. Radeljak S, Seiwerth S, et al. BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line. Melanoma Research. 2004;14(4):A14-A15 (conference abstract). Study conditions: In vitro, SK-Mel-1 human melanoma cells at 2ng and 10ng concentrations. Authored by Sikiric-affiliated researchers. Never independently replicated. Finding: BPC-157 lowered total S-phase fraction (cell division) up to 55% in SK-Mel-1 melanoma cells compared to controls.
3. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1451. Published commentary (not original research). Finding: No published in vivo data demonstrate that BPC-157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis. The Radeljak 2004 study remains unreplicated. BPC-157 activates FAK-paxillin signaling, a known pathway in cancer cell invasion.
4. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. Finding: BPC-157 should be considered investigational until well-designed human trials are conducted and published.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness